We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Deepens Personalized Care Through Platform Expansion
Read MoreHide Full Article
Key Takeaways
Hims & Hers is evolving from DTC telehealth into a broader personalized, digital-first platform.
Hims & Hers launched comprehensive lab testing in 2025 and added testosterone plus menopause programs.
HIMS is building pharmacies and fulfillment operations, while expanding across Canada, the U.K. and Europe.
Hims & Hers Health, Inc. (HIMS - Free Report) has progressed beyond a direct-to-consumer (DTC) telehealth provider into a broader healthcare technology platform centered on personalized, digital-first care delivery. Its platform integrates telehealth consultations, electronic medical records, digital prescriptions, cloud pharmacy fulfillment and personalization capabilities to streamline the patient experience across specialties such as weight loss, hormone health, dermatology, mental health and sexual wellness. Through its digital infrastructure and provider network, HIMS is positioning itself as a scalable healthcare platform rather than a traditional healthcare services company.
The company’s technology stack, proprietary algorithms and data analytics capabilities are designed to support ongoing clinical management, recurring subscriptions and personalized treatment plans. Hims & Hers also continues expanding its platform through diagnostics and preventative care initiatives. In 2025, the company launched comprehensive laboratory testing intended to support earlier health-risk identification and more proactive care management. It also broadened its specialty offerings with testosterone, menopause and perimenopause support programs, reflecting its strategy of deepening engagement across multiple chronic and lifestyle-related conditions.
Apart from its core telehealth operations, Hims & Hers is building a vertically integrated healthcare infrastructure that includes pharmacies, fulfillment operations and digital care delivery systems. The company has also continued expanding internationally across Canada, the U.K. and parts of Europe, while pursuing additional growth opportunities through strategic partnerships and acquisitions. Together, these developments underscore how HIMS is leveraging technology, data and integrated healthcare operations to build a more personalized and accessible healthcare ecosystem.
GDRX & TEM Scaling AI-Driven Healthcare Platforms
GoodRx Holdings, Inc. (GDRX - Free Report) is evolving into a healthcare technology platform that combines prescription savings, telemedicine, pharmacy integration and manufacturer-sponsored affordability programs to improve medication access and price transparency across the healthcare ecosystem. The company has launched GoodRx Employer Direct, expanded RxSmartSaver at Giant Eagle pharmacies and introduced access to oral GLP-1 treatments, including the Wegovy pill, Foundayo and Ozempic pill, through its nationwide pharmacy network. GoodRx also strengthened its platform through Pharma Direct partnerships, enabling scalable consumer-direct pricing and integrated healthcare access solutions.
Tempus AI, Inc. (TEM - Free Report) is advancing as a healthcare technology platform that combines AI, diagnostics and clinical data solutions to support precision medicine and guideline-concordant care. Tempus AI recently launched its automated “Active Follow-Up” service to improve patient management and introduced the ArteraAI Prostate Test for metastatic patients within the Tempus ecosystem. TEM also announced a novel pan-cancer HRD-RNA algorithm to enhance biomarker discovery, reinforcing Tempus AI’s focus on integrating AI-driven tools into oncology and clinical decision-making.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 26.1% year to date compared with the industry’s decline of 24.1%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.8X is lower than the industry’s average of 3.2X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 149.1% plunge compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Deepens Personalized Care Through Platform Expansion
Key Takeaways
Hims & Hers Health, Inc. (HIMS - Free Report) has progressed beyond a direct-to-consumer (DTC) telehealth provider into a broader healthcare technology platform centered on personalized, digital-first care delivery. Its platform integrates telehealth consultations, electronic medical records, digital prescriptions, cloud pharmacy fulfillment and personalization capabilities to streamline the patient experience across specialties such as weight loss, hormone health, dermatology, mental health and sexual wellness. Through its digital infrastructure and provider network, HIMS is positioning itself as a scalable healthcare platform rather than a traditional healthcare services company.
The company’s technology stack, proprietary algorithms and data analytics capabilities are designed to support ongoing clinical management, recurring subscriptions and personalized treatment plans. Hims & Hers also continues expanding its platform through diagnostics and preventative care initiatives. In 2025, the company launched comprehensive laboratory testing intended to support earlier health-risk identification and more proactive care management. It also broadened its specialty offerings with testosterone, menopause and perimenopause support programs, reflecting its strategy of deepening engagement across multiple chronic and lifestyle-related conditions.
Apart from its core telehealth operations, Hims & Hers is building a vertically integrated healthcare infrastructure that includes pharmacies, fulfillment operations and digital care delivery systems. The company has also continued expanding internationally across Canada, the U.K. and parts of Europe, while pursuing additional growth opportunities through strategic partnerships and acquisitions. Together, these developments underscore how HIMS is leveraging technology, data and integrated healthcare operations to build a more personalized and accessible healthcare ecosystem.
GDRX & TEM Scaling AI-Driven Healthcare Platforms
GoodRx Holdings, Inc. (GDRX - Free Report) is evolving into a healthcare technology platform that combines prescription savings, telemedicine, pharmacy integration and manufacturer-sponsored affordability programs to improve medication access and price transparency across the healthcare ecosystem. The company has launched GoodRx Employer Direct, expanded RxSmartSaver at Giant Eagle pharmacies and introduced access to oral GLP-1 treatments, including the Wegovy pill, Foundayo and Ozempic pill, through its nationwide pharmacy network. GoodRx also strengthened its platform through Pharma Direct partnerships, enabling scalable consumer-direct pricing and integrated healthcare access solutions.
Tempus AI, Inc. (TEM - Free Report) is advancing as a healthcare technology platform that combines AI, diagnostics and clinical data solutions to support precision medicine and guideline-concordant care. Tempus AI recently launched its automated “Active Follow-Up” service to improve patient management and introduced the ArteraAI Prostate Test for metastatic patients within the Tempus ecosystem. TEM also announced a novel pan-cancer HRD-RNA algorithm to enhance biomarker discovery, reinforcing Tempus AI’s focus on integrating AI-driven tools into oncology and clinical decision-making.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 26.1% year to date compared with the industry’s decline of 24.1%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.8X is lower than the industry’s average of 3.2X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 149.1% plunge compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.